Regeneron Pharmaceuticals, Inc. (REGN) Earnings Yield: 6.75%
Is Regeneron Pharmaceuticals, Inc.’s earnings yield high or low?
Regeneron Pharmaceuticals, Inc.'s earnings yield of 6.75% is in line with its 5-year average of 6.37%, around the middle of its 5-year range (3.08%–12.87%).
The earnings yield for Regeneron Pharmaceuticals, Inc. (REGN) is 6.75% as of Wednesday, June 10, 2026. It is above its 12-month average by 8.38% (6.23%).
REGN Earnings Yield Chart
REGN Average Earnings Yield Chart
REGN Current vs Average Earnings Yield Chart
REGN Earnings Yield Metrics
EARNINGS YIELD
6.75%
EARNINGS YIELD AVG TTM
6.23%
EARNINGS YIELD AVG 3Y
5.12%
EARNINGS YIELD AVG 5Y
6.37%
EARNINGS YIELD AVG 10Y
5.12%
EARNINGS YIELD AVG 15Y
4.17%
EARNINGS YIELD AVG 20Y
4.17%
CURRENT VS TTM AVG
+8.38%
CURRENT VS 3Y AVG
+31.85%
CURRENT VS 5Y AVG
+6.01%
CURRENT VS 10Y AVG
+31.71%
CURRENT VS 15Y AVG
+61.96%
CURRENT VS 20Y AVG
+61.96%
REGN Competitors' Earnings Yield
| NAME | MARKET CAP | EARNINGS YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. (REGN) | — | 6.75% | 6.23% | 5.12% | 6.37% |
| Cigna Corporation (CI) | $78.25B | 7.97% | 7.38% | 5.81% | 6.73% |
| IDEXX Laboratories, Inc. (IDXX) | $44.47B | 2.41% | 2.01% | 2.07% | 1.94% |
| Humana Inc. (HUM) | $43.78B | 2.56% | 4.76% | 4.86% | 4.86% |
| Elevance Health Inc. (ELV) | $87.43B | 5.84% | 7.31% | 6.27% | 5.78% |
| Agilent Technologies, Inc. (A) | $37.17B | 3.78% | 3.45% | 3.39% | 3.16% |
| Zoetis Inc. (ZTS) | $34.20B | 7.40% | 4.72% | 3.52% | 3.07% |
| Centene Corporation (CNC) | $31.94B | N/A | 11.79% | 7.73% | 6.10% |
| IQVIA Holdings Inc. (IQV) | $30.60B | 4.40% | 3.95% | 3.55% | 3.02% |
| DexCom, Inc. (DXCM) | $29.24B | 3.09% | 2.56% | 1.80% | 1.31% |
Earnings Yield vs P/E Ratio
Earnings Yield
6.75%
EPS ÷ Price
P/E Ratio
14.8
Price ÷ EPS
Formula: Earnings Yield = (EPS / Price) × 100
Earnings Yield is simply the inverse of P/E. A P/E of 20 equals a 5% earnings yield.
How earnings yield is used:
- It expresses earnings relative to share price as a percentage
- It can be compared with FCF yield and dividend yield
- It can be compared with bond yields because both are percentages
- It is mathematically the inverse of the P/E ratio
Regeneron Pharmaceuticals, Inc. Earnings Yield Formula & Definition
Earnings Yield = EPS (TTM) / Share Price
Earnings yield is the inverse of the PE ratio, expressing trailing earnings as a percentage of price. Higher is cheaper.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Regeneron Pharmaceuticals, Inc. Earnings Yield FAQ
- What is the earnings yield for Regeneron Pharmaceuticals, Inc. (REGN)?
- The earnings yield for REGN stock is 6.75%.
- Is Regeneron Pharmaceuticals, Inc.'s earnings yield high or low?
- Regeneron Pharmaceuticals, Inc.'s earnings yield of 6.75% is in line with its 5-year average of 6.37%, around the middle of its 5-year range (3.08%–12.87%).
- What is the TTM average earnings yield for Regeneron Pharmaceuticals, Inc. (REGN)?
- The TTM average earnings yield for REGN stock is 6.23%.
- What is the 3Y average earnings yield for Regeneron Pharmaceuticals, Inc. (REGN)?
- The 3Y average earnings yield for REGN stock is 5.12%.
- What is the 5Y average earnings yield for Regeneron Pharmaceuticals, Inc. (REGN)?
- The 5Y average earnings yield for REGN stock is 6.37%.
- What is the 10Y average earnings yield for Regeneron Pharmaceuticals, Inc. (REGN)?
- The 10Y average earnings yield for REGN stock is 5.12%.
- What is the 15Y average earnings yield for Regeneron Pharmaceuticals, Inc. (REGN)?
- The 15Y average earnings yield for REGN stock is 4.17%.
- What is the 20Y average earnings yield for Regeneron Pharmaceuticals, Inc. (REGN)?
- The 20Y average earnings yield for REGN stock is 4.17%.
Regeneron Pharmaceuticals, Inc. Earnings Yield History
| DATE | EARNINGS YIELD |
|---|---|
| 2026-06-10 | 6.75% |
| 2026-06-09 | 6.66% |
| 2026-06-08 | 6.71% |
| 2026-06-05 | 6.46% |
| 2026-06-04 | 6.53% |
| 2026-06-03 | 6.63% |
| 2026-06-02 | 6.81% |
| 2026-06-01 | 6.83% |
| 2026-05-29 | 6.68% |
| 2026-05-28 | 6.61% |
| 2026-05-27 | 6.54% |
| 2026-05-26 | 6.47% |
| 2026-05-22 | 6.42% |
| 2026-05-21 | 6.39% |
| 2026-05-20 | 6.32% |
| 2026-05-19 | 6.51% |
| 2026-05-18 | 6.52% |
| 2026-05-15 | 5.88% |
| 2026-05-14 | 5.76% |
| 2026-05-13 | 5.70% |
| 2026-05-12 | 5.67% |
| 2026-05-11 | 5.76% |
| 2026-05-08 | 5.74% |
| 2026-05-07 | 5.79% |
| 2026-05-06 | 5.69% |
| 2026-05-05 | 5.84% |
| 2026-05-04 | 5.79% |
| 2026-05-01 | 5.85% |
| 2026-04-30 | 5.80% |
| 2026-04-29 | 5.98% |
| 2026-04-28 | 5.68% |
| 2026-04-27 | 5.58% |
| 2026-04-24 | 5.53% |
| 2026-04-23 | 5.43% |
| 2026-04-22 | 5.57% |
| 2026-04-21 | 5.56% |
| 2026-04-20 | 5.55% |
| 2026-04-17 | 5.54% |
| 2026-04-16 | 5.57% |
| 2026-04-15 | 5.51% |
| 2026-04-14 | 5.50% |
| 2026-04-13 | 5.57% |
| 2026-04-10 | 5.55% |
| 2026-04-09 | 5.41% |
| 2026-04-08 | 5.36% |
| 2026-04-07 | 5.47% |
| 2026-04-06 | 5.45% |
| 2026-04-02 | 5.46% |
| 2026-04-01 | 5.35% |
| 2026-03-31 | 5.38% |
| 2026-03-30 | 5.55% |
| 2026-03-27 | 5.63% |
| 2026-03-26 | 5.49% |
| 2026-03-25 | 5.55% |
| 2026-03-24 | 5.60% |
| 2026-03-23 | 5.64% |
| 2026-03-20 | 5.67% |
| 2026-03-19 | 5.64% |
| 2026-03-18 | 5.59% |
| 2026-03-17 | 5.48% |
| 2026-03-16 | 5.49% |
| 2026-03-13 | 5.57% |
| 2026-03-12 | 5.57% |
| 2026-03-11 | 5.36% |
| 2026-03-10 | 5.38% |
| 2026-03-09 | 5.32% |
| 2026-03-06 | 5.47% |
| 2026-03-05 | 5.43% |
| 2026-03-04 | 5.28% |
| 2026-03-03 | 5.42% |
| 2026-03-02 | 5.25% |
| 2026-02-27 | 5.32% |
| 2026-02-26 | 5.39% |
| 2026-02-25 | 5.30% |
| 2026-02-24 | 5.38% |
| 2026-02-23 | 5.28% |
| 2026-02-20 | 5.33% |
| 2026-02-19 | 5.31% |
| 2026-02-18 | 5.25% |
| 2026-02-17 | 5.24% |
| 2026-02-13 | 5.17% |
| 2026-02-12 | 5.30% |
| 2026-02-11 | 5.34% |
| 2026-02-10 | 5.51% |
| 2026-02-09 | 5.33% |
| 2026-02-06 | 5.29% |
| 2026-02-05 | 5.42% |
| 2026-02-04 | 5.36% |
| 2026-02-03 | 5.50% |
| 2026-02-02 | 5.53% |
| 2026-01-30 | 5.63% |
| 2026-01-29 | 5.57% |
| 2026-01-28 | 5.56% |
| 2026-01-27 | 5.41% |
| 2026-01-26 | 5.48% |
| 2026-01-23 | 5.54% |
| 2026-01-22 | 5.53% |
| 2026-01-21 | 5.57% |
| 2026-01-20 | 5.69% |
| 2026-01-16 | 5.70% |
| 2026-01-15 | 5.63% |
| 2026-01-14 | 5.54% |
| 2026-01-13 | 5.50% |
| 2026-01-12 | 5.44% |
| 2026-01-09 | 5.24% |
| 2026-01-08 | 5.21% |
| 2026-01-07 | 5.14% |
| 2026-01-06 | 5.38% |
| 2026-01-05 | 5.47% |
| 2026-01-02 | 5.38% |
| 2025-12-31 | 5.41% |
| 2025-12-30 | 5.40% |
| 2025-12-29 | 5.35% |
| 2025-12-26 | 5.32% |
| 2025-12-24 | 5.33% |
| 2025-12-23 | 5.32% |
| 2025-12-22 | 5.36% |
| 2025-12-19 | 5.44% |
| 2025-12-18 | 5.58% |
| 2025-12-17 | 5.57% |
| 2025-12-16 | 5.60% |
| 2025-12-15 | 5.55% |
| 2025-12-12 | 5.63% |
| 2025-12-11 | 5.59% |
| 2025-12-10 | 5.75% |
| 2025-12-09 | 6.03% |
| 2025-12-08 | 5.94% |
| 2025-12-05 | 5.81% |
| 2025-12-04 | 5.78% |
| 2025-12-03 | 5.77% |
| 2025-12-02 | 5.63% |
| 2025-12-01 | 5.57% |
| 2025-11-28 | 5.35% |
| 2025-11-26 | 5.32% |
| 2025-11-25 | 5.31% |
| 2025-11-24 | 5.49% |
| 2025-11-21 | 5.52% |
| 2025-11-20 | 5.67% |
| 2025-11-19 | 5.94% |
| 2025-11-18 | 5.76% |
| 2025-11-17 | 5.93% |
| 2025-11-14 | 6.02% |
| 2025-11-13 | 6.01% |
| 2025-11-12 | 6.13% |
| 2025-11-11 | 6.19% |
| 2025-11-10 | 6.38% |
| 2025-11-07 | 6.35% |
| 2025-11-06 | 6.46% |
| 2025-11-05 | 6.48% |
| 2025-11-04 | 6.65% |
| 2025-11-03 | 6.50% |
| 2025-10-31 | 6.41% |
| 2025-10-30 | 6.39% |
| 2025-10-29 | 6.40% |
| 2025-10-28 | 6.38% |
| 2025-10-27 | 6.78% |
| 2025-10-24 | 6.86% |
| 2025-10-23 | 6.89% |
| 2025-10-22 | 6.78% |
| 2025-10-21 | 6.85% |
| 2025-10-20 | 6.88% |
| 2025-10-17 | 6.86% |
| 2025-10-16 | 6.97% |
| 2025-10-15 | 6.88% |
| 2025-10-14 | 6.93% |
| 2025-10-13 | 7.11% |
| 2025-10-10 | 7.03% |
| 2025-10-09 | 6.96% |
| 2025-10-08 | 7.04% |
| 2025-10-07 | 6.80% |
| 2025-10-06 | 6.78% |
| 2025-10-03 | 6.61% |
| 2025-10-02 | 6.61% |
| 2025-10-01 | 6.61% |
| 2025-09-30 | 7.06% |
| 2025-09-29 | 7.08% |
| 2025-09-26 | 7.04% |
| 2025-09-25 | 7.14% |
| 2025-09-24 | 6.88% |
| 2025-09-23 | 6.99% |
| 2025-09-22 | 6.66% |
| 2025-09-19 | 6.70% |
| 2025-09-18 | 6.63% |
| 2025-09-17 | 6.78% |
| 2025-09-16 | 6.90% |
| 2025-09-15 | 6.93% |
| 2025-09-12 | 7.09% |
| 2025-09-11 | 6.98% |
| 2025-09-10 | 7.14% |
| 2025-09-09 | 7.13% |
| 2025-09-08 | 7.11% |
| 2025-09-05 | 6.92% |
| 2025-09-04 | 7.00% |
| 2025-09-03 | 7.04% |
| 2025-09-02 | 6.87% |
| 2025-08-29 | 6.84% |
| 2025-08-28 | 6.84% |
| 2025-08-27 | 6.76% |
| 2025-08-26 | 6.75% |
| 2025-08-25 | 6.93% |
| 2025-08-22 | 6.73% |
| 2025-08-21 | 6.64% |
| 2025-08-20 | 6.72% |
| 2025-08-19 | 6.94% |
| 2025-08-18 | 6.92% |
| 2025-08-15 | 6.84% |
| 2025-08-14 | 7.01% |
| 2025-08-13 | 7.07% |
| 2025-08-12 | 7.13% |
| 2025-08-11 | 7.27% |
| 2025-08-08 | 7.05% |
| 2025-08-07 | 7.09% |
| 2025-08-06 | 7.15% |
| 2025-08-05 | 6.96% |
| 2025-08-04 | 6.94% |
| 2025-08-01 | 7.10% |
| 2025-07-31 | 7.20% |
| 2025-07-30 | 7.08% |
| 2025-07-29 | 7.04% |
| 2025-07-28 | 7.03% |
| 2025-07-25 | 6.97% |
| 2025-07-24 | 6.96% |
| 2025-07-23 | 6.86% |
| 2025-07-22 | 7.00% |
| 2025-07-21 | 7.20% |
| 2025-07-18 | 7.24% |
| 2025-07-17 | 7.14% |
| 2025-07-16 | 7.17% |
| 2025-07-15 | 7.17% |
| 2025-07-14 | 6.88% |
| 2025-07-11 | 6.92% |
| 2025-07-10 | 7.02% |
| 2025-07-09 | 7.11% |
| 2025-07-08 | 7.17% |
| 2025-07-07 | 7.30% |
| 2025-07-03 | 7.18% |
| 2025-07-02 | 7.17% |
| 2025-07-01 | 7.34% |
| 2025-06-30 | 7.48% |
| 2025-06-27 | 7.54% |
| 2025-06-26 | 7.54% |
| 2025-06-25 | 7.55% |
| 2025-06-24 | 7.52% |
| 2025-06-23 | 7.67% |
| 2025-06-20 | 7.70% |
| 2025-06-18 | 7.65% |
| 2025-06-17 | 7.72% |
| 2025-06-16 | 7.51% |
| 2025-06-13 | 7.42% |
| 2025-06-12 | 7.52% |
| 2025-06-11 | 7.58% |
| 2025-06-10 | 7.50% |
| 2025-06-09 | 7.59% |
| 2025-06-06 | 7.96% |
| 2025-06-05 | 8.13% |
| 2025-06-04 | 8.10% |
| 2025-06-03 | 8.05% |
| 2025-06-02 | 8.00% |
| 2025-05-30 | 8.01% |
| 2025-05-29 | 6.49% |
Showing the most recent 260 of 3,425 data points. The chart above shows the full history.
Related Metrics
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Leonard S. Schleifer